RxDoctor Payments Data

Megan Guntrum, MD

Family Medicine · Houston, TXNPI 1679102412

Payments from drug & device makers

$2,442in general payments, 2019–2025

Across 125 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$465
  • AstraZeneca$275
  • Pfizer$268
  • Lilly USA, LLC$237
  • GSK$228
  • Novartis$191
  • plus $777 from 15 others

What the payments were for

  • Food & beverage$2,442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,442 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,817
Medicare patients
101
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin86$103,193
OzempicSemaglutide56$87,711
EliquisApixaban43$67,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$21,876
MounjaroTirzepatide17$21,622
FarxigaDapagliflozin Propanediol11$12,754
PaxlovidNirmatrelvir/Ritonavir11$5,651
Breo ElliptaFluticasone/Vilanterol12$4,751
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,619
Levothyroxine Sodium179$3,390
Atorvastatin Calcium247$3,092
Albuterol Sulfate HfaAlbuterol Sulfate76$2,526
SynthroidLevothyroxine Sodium22$2,490
Ventolin HfaAlbuterol Sulfate13$1,985
Gabapentin77$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$118$103,19386 claims
Novo NordiskOzempic$465$87,71156 claims
PfizerEliquis, Paxlovid$268$73,19154 claims
GSKTrelegy Ellipta, Breo Ellipta$228$26,62741 claims
Lilly USA, LLCMounjaro$237$21,62217 claims
AstraZenecaFarxiga$275$12,75411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →